Matrix bound nanovesicle-associated IL-33 activates a pro-remodeling macrophage phenotype via a non-canonical, ST2-independent pathway
Journal of Immunology and Regenerative Medicine · 2019
DOI: 10.1016/j.regen.2019.01.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunology and Regenerative Medicine, 2019. Verfasst von George S Hussey und 6 weiteren Autor:innen. Beteiligte Einrichtung: McGowan Institute for Regenerative Medicine, University of Pittsburgh, 450 Technology Drive, Suite 300, Pittsburgh, PA 15219-3110, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
The regenerative healing response of injured skeletal muscle is dependent upon an appropriately timed switch from a local type-I to a type-II immune response. Biologic scaffolds derived from extracellular matrix (ECM) have been shown to facilitate a macrophage phenotype transition that leads to downstream site-appropriate functional tissue deposition and myogenesis. However, the mechanisms by which ECM directs the switching of immune cell phenotype are only partially understood. Herein, we provide the first evidence that matrix bound nanovesicles (MBV) embedded within ECM-scaffolds are a rich and stable source of interleukin-33 (IL-33), an alarmin/cytokine with emerging reparative properties. We show that IL-33 encapsulated within MBV bypass the classical IL33/ST2 receptor signaling pathway to direct macrophage differentiation into the reparative, pro-remodeling M2 phenotype, which in turn facilitates myogenesis of skeletal muscle progenitor cells. Our results suggest the potential of IL-33+ MBV as a clinical therapy to augment the restorative efficacy of existing ECM-based and non-ECM based approaches.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- McGowan Institute for Regenerative Medicine, University of Pittsburgh, 450 Technology Drive, Suite 300, Pittsburgh, PA 15219-3110, USA.
- Department of Surgery, School of Medicine, University of Pittsburgh, University of Pittsburgh Medical Center Presbyterian Hospital, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
- Department of Bioengineering, University of Pittsburgh, 3700 O'Hara Street, Pittsburgh, PA, 15261, USA.
- Thomas E. Starzl Transplantation Institute, University of Pittsburgh, University of Pittsburgh Medical Center Presbyterian Hospital, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
- Department of Immunology, School of Medicine, University of Pittsburgh, University of Pittsburgh Medical Center Presbyterian Hospital, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Förderung
- NIAMS NIH HHS
- NHLBI NIH HHS
- NIBIB NIH HHS
- NIH
Zitieren
APA
Hussey, G. S., Dziki, J. L., Lee, Y. C., Bartolacci, J. G., Behun, M., Turnquist, H. R., & Badylak, S. F. (2019). Matrix bound nanovesicle-associated IL-33 activates a pro-remodeling macrophage phenotype via a non-canonical, ST2-independent pathway. Journal of Immunology and Regenerative Medicine. https://doi.org/10.1016/j.regen.2019.01.001
Vancouver
Hussey GS, Dziki JL, Lee YC, Bartolacci JG, Behun M, Turnquist HR, et al. Matrix bound nanovesicle-associated IL-33 activates a pro-remodeling macrophage phenotype via a non-canonical, ST2-independent pathway. Journal of Immunology and Regenerative Medicine. 2019. doi:10.1016/j.regen.2019.01.001
BibTeX
@article{Hussey2019,
author = {Hussey, George S and Dziki, Jenna L and Lee, Yoojin C and Bartolacci, Joseph G and Behun, Marissa and Turnquist, Hēth R and Badylak, Stephen F},
title = {Matrix bound nanovesicle-associated IL-33 activates a pro-remodeling macrophage phenotype via a non-canonical, ST2-independent pathway},
journal = {Journal of Immunology and Regenerative Medicine},
year = {2019},
doi = {10.1016/j.regen.2019.01.001}
}
EUVIMED